Traditionally, benign and malignant diseases of the skeletal system have been evaluated with radiological investigations like X-ray, CT scan, or MRI. These have established themselves as modalities of choice because of wide availability and excellent anatomical details they provide. X-ray and CT scan have been able to provide excellent images of cortical bone while MRI depicts details of bone marrow and associated soft tissue like no other imaging modality can. In the last decade or so, there has been tremendous interest and advances in applications of positron emission tomography (PET) in the field of oncology. Particularly, 2-fleuro-2-deoxy-glucose (FDG) PET-CT has become a backbone of oncological imaging for various cancers, including the bone and bone marrow tumors.
Positron Emission Tomography Single Photon Emission Compute Tomography Bone Metastasis Standardize Uptake Value Skeletal Metastasis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
For Further Reading
Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76.PubMedCentralPubMedCrossRefGoogle Scholar
Cheng G, Kwee TC, Basu S, Alavi A. Critical considerations on the combined use of 18F-FDG and 18F-fluoride for PET assessment of metastatic bone disease. Eur J Nucl Med Mol Imaging. 2013;40:1141–5.PubMedCrossRefGoogle Scholar
Eubank WB, Mankoff DA. Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2004;34:224–40.PubMedCrossRefGoogle Scholar
Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356–67.PubMedGoogle Scholar
Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–92.PubMedCrossRefGoogle Scholar
Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med. 2000;27:1509–17.PubMedCrossRefGoogle Scholar